Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

Opinion
Video

Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.

Video content above is prompted by the following:

  • Could you discuss the key outcomes from the ARCHWAY trial for PDS?
  • The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline
Recent Videos
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.